Cargando…

Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review

Rationale: Physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PK) modelling approaches are widely accepted in non-radiopharmaceutical drug development and research, while there is no major role for these approaches in radiopharmaceutical development yet. In this review, a l...

Descripción completa

Detalles Bibliográficos
Autores principales: Siebinga, Hinke, de Wit-van der Veen, Berlinda J., Stokkel, Marcel D.M., Huitema, Alwin D.R., Hendrikx, Jeroen J.M.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706588/
https://www.ncbi.nlm.nih.gov/pubmed/36451855
http://dx.doi.org/10.7150/thno.77279
_version_ 1784840537312854016
author Siebinga, Hinke
de Wit-van der Veen, Berlinda J.
Stokkel, Marcel D.M.
Huitema, Alwin D.R.
Hendrikx, Jeroen J.M.A.
author_facet Siebinga, Hinke
de Wit-van der Veen, Berlinda J.
Stokkel, Marcel D.M.
Huitema, Alwin D.R.
Hendrikx, Jeroen J.M.A.
author_sort Siebinga, Hinke
collection PubMed
description Rationale: Physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PK) modelling approaches are widely accepted in non-radiopharmaceutical drug development and research, while there is no major role for these approaches in radiopharmaceutical development yet. In this review, a literature search was performed to specify different research purposes and questions that have previously been answered using both PBPK and population PK modelling for radiopharmaceuticals. Methods: The literature search was performed using the databases PubMed and Embase. Wide search terms included radiopharmaceutical, tracer, radioactivity, physiologically based pharmacokinetic model, PBPK, population pharmacokinetic model and nonlinear mixed-effects model. Results: Eight articles and twenty articles were included for this review based on this literature search for population PK modelling and PBPK modelling, respectively. Included population PK analyses showed to have an added value to develop predictive models for a population and to describe individual variability sources. Main purposes of PBPK models appeared related to optimizing treatment (planning), or more specifically: to find the optimal combination of peptide amount and radioactivity, to optimize treatment planning by reducing the number of measurements, to individualize treatment, to get insights in differences between pre-therapeutic and therapeutic scans or to understand inter-patient differences. Other main research subjects were regarding radiopharmaceutical comparisons, selecting ligands based on their peptide characteristics and gaining a better understanding of drug-drug interactions. Conclusions: The use of PK modelling approaches in radiopharmaceutical research remains scarce, but can be expanded to obtain a better understanding of PK and whole-body distribution of radiopharmaceuticals in general. PK modelling of radiopharmaceuticals has great potential for the nearby future and could contribute to the evolving research of radiopharmaceuticals.
format Online
Article
Text
id pubmed-9706588
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-97065882022-11-29 Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review Siebinga, Hinke de Wit-van der Veen, Berlinda J. Stokkel, Marcel D.M. Huitema, Alwin D.R. Hendrikx, Jeroen J.M.A. Theranostics Review Rationale: Physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PK) modelling approaches are widely accepted in non-radiopharmaceutical drug development and research, while there is no major role for these approaches in radiopharmaceutical development yet. In this review, a literature search was performed to specify different research purposes and questions that have previously been answered using both PBPK and population PK modelling for radiopharmaceuticals. Methods: The literature search was performed using the databases PubMed and Embase. Wide search terms included radiopharmaceutical, tracer, radioactivity, physiologically based pharmacokinetic model, PBPK, population pharmacokinetic model and nonlinear mixed-effects model. Results: Eight articles and twenty articles were included for this review based on this literature search for population PK modelling and PBPK modelling, respectively. Included population PK analyses showed to have an added value to develop predictive models for a population and to describe individual variability sources. Main purposes of PBPK models appeared related to optimizing treatment (planning), or more specifically: to find the optimal combination of peptide amount and radioactivity, to optimize treatment planning by reducing the number of measurements, to individualize treatment, to get insights in differences between pre-therapeutic and therapeutic scans or to understand inter-patient differences. Other main research subjects were regarding radiopharmaceutical comparisons, selecting ligands based on their peptide characteristics and gaining a better understanding of drug-drug interactions. Conclusions: The use of PK modelling approaches in radiopharmaceutical research remains scarce, but can be expanded to obtain a better understanding of PK and whole-body distribution of radiopharmaceuticals in general. PK modelling of radiopharmaceuticals has great potential for the nearby future and could contribute to the evolving research of radiopharmaceuticals. Ivyspring International Publisher 2022-11-14 /pmc/articles/PMC9706588/ /pubmed/36451855 http://dx.doi.org/10.7150/thno.77279 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Siebinga, Hinke
de Wit-van der Veen, Berlinda J.
Stokkel, Marcel D.M.
Huitema, Alwin D.R.
Hendrikx, Jeroen J.M.A.
Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
title Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
title_full Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
title_fullStr Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
title_full_unstemmed Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
title_short Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
title_sort current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706588/
https://www.ncbi.nlm.nih.gov/pubmed/36451855
http://dx.doi.org/10.7150/thno.77279
work_keys_str_mv AT siebingahinke currentuseandfuturepotentialofphysiologicallybasedpharmacokineticmodellingofradiopharmaceuticalsareview
AT dewitvanderveenberlindaj currentuseandfuturepotentialofphysiologicallybasedpharmacokineticmodellingofradiopharmaceuticalsareview
AT stokkelmarceldm currentuseandfuturepotentialofphysiologicallybasedpharmacokineticmodellingofradiopharmaceuticalsareview
AT huitemaalwindr currentuseandfuturepotentialofphysiologicallybasedpharmacokineticmodellingofradiopharmaceuticalsareview
AT hendrikxjeroenjma currentuseandfuturepotentialofphysiologicallybasedpharmacokineticmodellingofradiopharmaceuticalsareview